{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:00Z","timestamp":1786979940668,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical and Translational Medicine Research Project of Chinese Academy of Medical Sciences","award":["2023-I2M-C&T-B-107"],"award-info":[{"award-number":["2023-I2M-C&T-B-107"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-026"],"award-info":[{"award-number":["2022-PUMCH-C-026"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370142"],"award-info":[{"award-number":["82370142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232130"],"award-info":[{"award-number":["7232130"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06780-0","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T01:14:14Z","timestamp":1768612454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy"],"prefix":"10.1007","volume":"105","author":[{"given":"Lingxiao","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiru","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"17","key":"6780_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS (2018) Aplastic anemia. N Engl J Med 379(17):1643\u20131656","journal-title":"N Engl J Med"},{"issue":"17","key":"6780_CR2","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","volume":"117","author":"A Tichelli","year":"2011","unstructured":"Tichelli A, Schrezenmeier H, Socie G et al (2011) A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA working party of the European Group for Blood and Marrow Transplantation. Blood 117(17):4434\u20134441","journal-title":"Blood"},{"issue":"4","key":"6780_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3324\/haematol.12855","volume":"93","author":"NS Young","year":"2008","unstructured":"Young NS, Kaufman DW (2008) The epidemiology of acquired aplastic anemia. Haematologica 93(4):489\u2013492","journal-title":"Haematologica"},{"key":"6780_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100772","volume":"47","author":"R Iftikhar","year":"2021","unstructured":"Iftikhar R, Chaudhry QUN, Anwer F et al (2021) Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev 47:100772","journal-title":"Blood Rev"},{"issue":"4","key":"6780_CR5","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2002-04-1134","volume":"101","author":"N Frickhofen","year":"2003","unstructured":"Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study G (2003) Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101(4):1236\u20131242","journal-title":"Blood"},{"issue":"11","key":"6780_CR6","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00277-020-04271-4","volume":"99","author":"B Drexler","year":"2020","unstructured":"Drexler B, Zurbriggen F, Diesch T et al (2020) Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation. Ann Hematol 99(11):2529\u20132538","journal-title":"Ann Hematol"},{"key":"6780_CR7","doi-asserted-by":"crossref","unstructured":"Dufour C, Svahn J, Bacigalupo A (2013) Severe Aplastic Anemia-Working Party of the E. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 48(2):174\u2013177.","DOI":"10.1038\/bmt.2012.222"},{"issue":"1","key":"6780_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood.2021012130","volume":"139","author":"BA Patel","year":"2022","unstructured":"Patel BA, Groarke EM, Lotter J et al (2022) Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood 139(1):34\u201343","journal-title":"Blood"},{"issue":"3","key":"6780_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I et al (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline. Br J Haematol 204(3):784\u2013804","journal-title":"Br J Haematol"},{"key":"6780_CR10","doi-asserted-by":"crossref","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. (2022) Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 386(1):11\u201323.","DOI":"10.1056\/NEJMoa2109965"},{"issue":"1","key":"6780_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1600-0609.2009.01237.x","volume":"83","author":"MK Song","year":"2009","unstructured":"Song MK, Chung JS, Joo YD et al (2009) Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol 83(1):72\u201378","journal-title":"Eur J Haematol"},{"issue":"11","key":"6780_CR12","first-page":"766","volume":"32","author":"LY Liang","year":"2011","unstructured":"Liang LY, Zhang L, Jing LP et al (2011) Effects of concentration of cyclosporine A on the early response to immunosuppressive therapy in severe aplastic anemia. Zhonghua Xue Ye Xue Za Zhi 32(11):766\u2013771","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"8","key":"6780_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/01.TP.0000085046.39523.D5","volume":"76","author":"K Midtvedt","year":"2003","unstructured":"Midtvedt K, Fauchald P, Bergan S et al (2003) C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 76(8):1236\u20131238","journal-title":"Transplantation"},{"issue":"6","key":"6780_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","volume":"24","author":"A Fahr","year":"1993","unstructured":"Fahr A (1993) Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24(6):472\u2013495","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"6780_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/08923973.2021.1966033","volume":"43","author":"H Parlakpinar","year":"2021","unstructured":"Parlakpinar H, Gunata M (2021) Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacol Immunotoxicol 43(6):651\u2013665","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"Suppl 36","key":"6780_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2133.1990.tb02884.x","volume":"122","author":"J Mason","year":"1990","unstructured":"Mason J (1990) Renal side-effects of cyclosporin A. Br J Dermatol 122(Suppl 36):71\u201377","journal-title":"Br J Dermatol"},{"issue":"12","key":"6780_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15912","volume":"35","author":"J Chojnacka-Purpurowicz","year":"2022","unstructured":"Chojnacka-Purpurowicz J, Wygonowska E, Placek W, Owczarczyk-Saczonek A (2022) Cyclosporine-induced gingival overgrowth-review. Dermatol Ther 35(12):e15912","journal-title":"Dermatol Ther"},{"issue":"2","key":"6780_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2141.1988.tb02460.x","volume":"70","author":"A Bacigalupo","year":"1988","unstructured":"Bacigalupo A, Hows J, Gluckman E et al (1988) Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 70(2):177\u2013182","journal-title":"Br J Haematol"},{"issue":"1","key":"6780_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood.V48.1.63.63","volume":"48","author":"BM Camitta","year":"1976","unstructured":"Camitta BM, Thomas ED, Nathan DG et al (1976) Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 48(1):63\u201370","journal-title":"Blood"},{"issue":"11","key":"6780_CR20","first-page":"881","volume":"43","author":"Red Blood Cell Disease Group CSoHCMA","year":"2022","unstructured":"Red Blood Cell Disease Group CSoHCMA (2022) Guidelines for the diagnosis and management of aplastic anemia in China (2022). Zhonghua Xue Ye Xue Za Zhi 43(11):881\u2013888","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"6","key":"6780_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","volume":"45","author":"D Faulds","year":"1993","unstructured":"Faulds D, Goa KL, Benfield P (1993) Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45(6):953\u20131040","journal-title":"Drugs"},{"issue":"13","key":"6780_CR22","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2165\/00003495-200161130-00006","volume":"61","author":"CJ Dunn","year":"2001","unstructured":"Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL (2001) Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 61(13):1957\u20132016","journal-title":"Drugs"},{"issue":"5","key":"6780_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1056\/NEJM198908033210504","volume":"321","author":"HY Lin","year":"1989","unstructured":"Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH (1989) Cyclosporine-induced hyperuricemia and gout. N Engl J Med 321(5):287\u2013292","journal-title":"N Engl J Med"},{"issue":"3","key":"6780_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0272-6386(12)80095-3","volume":"18","author":"DE Hricik","year":"1991","unstructured":"Hricik DE, Mayes JT, Schulak JA (1991) Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 18(3):353\u2013358","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"6780_CR25","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/ATVBAHA.115.307030","volume":"36","author":"M Kockx","year":"2016","unstructured":"Kockx M, Glaros E, Leung B et al (2016) Low-density lipoprotein receptor-dependent and low-density lipoprotein receptor-independent mechanisms of cyclosporin A-induced dyslipidemia. Arterioscler Thromb Vasc Biol 36(7):1338\u20131349","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"6780_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MOL.0000000000000363","volume":"27","author":"M Kockx","year":"2016","unstructured":"Kockx M, Kritharides L (2016) Hyperlipidaemia in immunosuppression. Curr Opin Lipidol 27(6):631\u2013632","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"6780_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2165\/00002018-199920050-00004","volume":"20","author":"SJ Taler","year":"1999","unstructured":"Taler SJ, Textor SC, Canzanello VJ, Schwartz L (1999) Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 20(5):437\u2013449","journal-title":"Drug Saf"},{"issue":"2","key":"6780_CR28","doi-asserted-by":"publisher","first-page":"e13948","DOI":"10.1111\/apha.13948","volume":"238","author":"ZX Gao","year":"2023","unstructured":"Gao ZX, Zhou R, Li MY et al (2023) Activation of Kir4.1\/Kir5.1 contributes to the cyclosporin A-induced stimulation of the renal NaCl cotransporter and hyperkalemic hypertension. Acta Physiol (Oxf) 238(2):e13948","journal-title":"Acta Physiol (Oxf)"},{"issue":"10","key":"6780_CR29","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1517\/14740338.2015.1083974","volume":"14","author":"P Malvezzi","year":"2015","unstructured":"Malvezzi P, Rostaing L (2015) The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf 14(10):1531\u20131546","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"6780_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1464-410X.1987.tb09129.x","volume":"60","author":"A Kondo","year":"1987","unstructured":"Kondo A, Otani T (1987) Correction of reflux with the ureteric crossover method. Clinical experience in 50 patients. Br J Urol 60(1):36\u201338","journal-title":"Br J Urol"},{"issue":"4","key":"6780_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0022034515571265","volume":"94","author":"PC Trackman","year":"2015","unstructured":"Trackman PC, Kantarci A (2015) Molecular and clinical aspects of drug-induced gingival overgrowth. J Dent Res 94(4):540\u2013546","journal-title":"J Dent Res"},{"issue":"3","key":"6780_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.abd.2019.08.027","volume":"95","author":"KF Souza","year":"2020","unstructured":"Souza KF, Andrade P, Cassia FF, Castro MCR (2020) Cyclosporine-induced childhood generalized hypertrichosis. An Bras Dermatol 95(3):402\u2013403","journal-title":"An Bras Dermatol"},{"issue":"5","key":"6780_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.7555\/JBR.26.20110067","volume":"26","author":"W Xu","year":"2012","unstructured":"Xu W, Fan W, Yao K (2012) Cyclosporine A stimulated hair growth from mouse vibrissae follicles in an organ culture model. J Biomed Res 26(5):372\u2013380","journal-title":"J Biomed Res"},{"issue":"7","key":"6780_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1432-2277.2005.00151.x","volume":"18","author":"B Nashan","year":"2005","unstructured":"Nashan B, Bock A, Bosmans JL et al (2005) Use of Neoral C monitoring: a European consensus. Transpl Int 18(7):768\u2013778","journal-title":"Transpl Int"},{"issue":"1","key":"6780_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ndt\/gfg434","volume":"19","author":"G Einecke","year":"2004","unstructured":"Einecke G, Mai I, Fritsche L et al (2004) The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 19(1):215\u2013222","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"6780_CR36","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1097\/01.TP.0000068868.01424.61","volume":"75","author":"E Cole","year":"2003","unstructured":"Cole E, Maham N, Cardella C et al (2003) Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 75(12):2086\u20132090","journal-title":"Transplantation"},{"issue":"2","key":"6780_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1681\/ASN.V112343","volume":"11","author":"E David-Neto","year":"2000","unstructured":"David-Neto E, Lemos FBC, Arai Furusawa E et al (2000) Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol 11(2):343\u2013349","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"6780_CR38","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/00007890-199812270-00009","volume":"66","author":"M Cantarovich","year":"1998","unstructured":"Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P (1998) Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66(12):1621\u20131627","journal-title":"Transplantation"},{"issue":"2","key":"6780_CR39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.clpt.2005.04.008","volume":"78","author":"M Fukudo","year":"2005","unstructured":"Fukudo M, Yano I, Masuda S et al (2005) Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 78(2):168\u2013181","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"6780_CR40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/11313380-000000000-00000","volume":"48","author":"P Falck","year":"2009","unstructured":"Falck P, Midtvedt K, Van Le TT et al (2009) A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. Clin Pharmacokinet 48(9):615\u2013623","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"6780_CR41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1208\/s12248-013-9500-8","volume":"15","author":"K Han","year":"2013","unstructured":"Han K, Pillai VC, Venkataramanan R (2013) Population pharmacokinetics of cyclosporine in transplant recipients. AAPS J 15(4):901\u2013912","journal-title":"AAPS J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06780-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06780-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06780-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:32:56Z","timestamp":1770262376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06780-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6780"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06780-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee (IIT2021008-EC-1) and conducted in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}